Sign up Australia
Proactive Investors - Run By Investors For Investors

FDA approves Avita Medical ReCell® Spray-On Skin clinical trial in USA

FDA approves Avita Medical ReCell® Spray-On Skin clinical trial in USA

Avita Medical (ASX: AVH) has received approval from the United States Food and Drug Administration (FDA) to begin its US clinical trial for ReCell® Spray-On Skin.

This represents the first stand-alone regenerative point-of-care device enabling surgeons to treat burns, wounds and chronic skin defects using the patient’s own cells.

The company (as Clinical Cell Culture) had previously commenced US trials in 2006 under a conditional approval; due to excessively restrictive inclusion criteria patient recruitment was very low. 

Additionally, the company had failed to adequately address concerns of the FDA regarding study endpoints, patient follow-up and statistical analysis of collected data. The trial was suspended by Avita in July 2008. Working closely with the FDA, the company’s regulatory advisory group and key clinicians, the company recently submitted a modified study protocol.

The study will yield a randomised, controlled, clinical comparison with the current standard of care in treating burn wounds.

The company has appointed 10 clinical sites to participate in the trials; patient enrolment is anticipated to commence in early 2010.

“Avita is now on track for its US regulatory approval process for ReCell,” said Dr William Dolphin, Chief Executive Officer of Avita Medical."

 “With the FDA protocol approval in place, our next steps are to obtain IRB approval at each site and train investigators in the use of ReCell prior to enrolment of initial subjects," he said."

“We now have a pragmatic and clinically feasible trial protocol in place and we are confident of successfully achieving the trial endpoints.”

Part of the funding for the clinical trial comes from a US$1.45 million grant from the US Army to help develop regenerative medicine through the recently initiated Armed Forces Institute for Regenerative Medicine (AFIRM).

“ReCell is a transformational technology that will fundamentally change the way we treat burns and other wounds” said Dr James Holmes of the Wake Forest Institute for Regenerative Medicine, Principle Investigator for the trial.

“When ReCell is approved for use in the United States there is no doubt that it will save the lives of burn victims.”

"What's available today is the same technology that was available 30 years ago," said Dr Holmes. "In a burn one is always working against time. ReCell will allow us to turn back the clock on all kinds of burns. We are very anxious to complete administrative details and commence enrolment for this important study.”

ReCell is currently cleared for sale in Australia, Europe, Canada and China.

View full AVH profile View Profile

Avita Medical Ltd Timeline

Related Articles

cells
July 31 2018
Life science generally is developing at an incredible speed, says Joe Anderson
cholesterol on a dial
September 24 2018
"The formation of ProBiotix Health and appointment of Adam Reynolds as chairman continues a successful strategy of building value in each division which is materialised by forming separate legal entities and taking them to a public listing,” said chief executive Stephen O’Hara
Widecells
September 28 2018
WideCells has undertaken a review of the business to deliver a strategy that will generate revenue, reduce overheads and achieve profitability

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use